
The US Food and Drug Administration FDA has given orphan drug priority status to Saniona's drug candidate Tesomet for treating hypothalamic obesity (HO), according to a press release on Monday.
"There are currently no FDA-approved medicines for hypothalamic obesity. Despite the devastating weight gain and hunger this rare disease can cause, there has been relatively little drug development specifically for HO," says Saniona Chief Medical Officer and Head of Clinical Development Rudolf Baumgartner in the press release.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app